Feb 05, 2025 5:30pm EST Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Feb 04, 2025 7:00am EST Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
Jan 31, 2025 8:38am EST Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
Jan 28, 2025 9:33am EST Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares
Jan 27, 2025 4:03pm EST Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares
Jan 22, 2025 10:59am EST Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
Jan 15, 2025 7:00am EST Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada
Dec 02, 2024 7:00am EST Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule
Nov 18, 2024 7:00am EST Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
